Nutritional supplement tested alongside immunotherapy in advanced lung cancer
Tests an immune-boosting nutritional supplement with immunotherapy in adults with advanced lung cancer.
Plain-language title generated from the registry record
Registry title: Immunonutrition for Improving the Efficacy of Immunotherapy in Patients With Metastatic Non-small Cell Lung Cancer
Key facts
- Where
- Pavia, ItalySee the site
Where in Italy
- Fondazione IRCCS Policlinico San MatteoPavia, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fondazione IRCCS Policlinico San Matteo di Pavia
- Trial code
- NCT05384873
- Record updated
- 4 November 2026
- Original description
The present study was designed to evaluate the efficacy of the early systematic provision of oral nutritional supplements enriched in immunonutrients in non-small lung cancer patients undergoing immunotherapy and receiving nutritional counselingRead full original descriptionShow less
Multicentre, Randomised, Open-label, Parallel-group Trial to Evaluate Immunonutrition in Improving Efficacy of Immunotherapy in Patients With Metastatic Non-small Cell Lung Cancer, Undergoing Systematic Nutritional Counseling
The present study was designed to evaluate the efficacy of the early systematic provision of oral nutritional supplements enriched in immunonutrients in non-small lung cancer patients undergoing immunotherapy and receiving nutritional counseling
Inclusion: Confirmed histological diagnosis of metastatic non-small cell lung cancer (both squamous and non-squamous histology); First-line treatment with immunotherapy (alone or in combination with chemotherapy) for metastatic disease by investigators' choice within the framework of good clinical practice and in agreement with current guidelines; Will to participate by providing written informed consent; Availability to administer oral supplements and immunotherapy with or without chemotherapy; Eastern Cooperative Oncology Group Performance Status ≤ 2; Life expectancy ≥ 6 months.
Exclusion: Age < 18 years; Inability to sign an informed consent; Indication to or ongoing artificial nutrition support (totally compromised spontaneous food-intake) and incapacity or unavailability to consume oral nutritional supplements.